Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.
Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.
Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...
Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback